Literature DB >> 21250845

Quantification of the anti-influenza drug zanamivir in plasma using high-throughput HILIC-MS/MS.

Niklas Lindegardh1, Warunee Hanpithakpong, Benjamas Kamanikom, Jeremy Farrar, Tran Tinh Hien, Pratap Singhasivanon, Nicholas J White, Nicholas P J Day.   

Abstract

BACKGROUND: parenteral zanamivir is a promising drug for the treatment of severe influenza. However, quantification of this polar drug in biological matrices has traditionally been difficult and the methods developed have been relatively insensitive.
RESULTS: a high-throughput bioanalytical method for the analysis of zanamivir in human plasma using SPE in the 96-well plate format and LC coupled to positive MS/MS has been developed and validated according to US FDA guidelines. The method uses 50 microl of plasma and covers a large working range from 1-50, 000 ng/ml with a LOD of 0.50 ng/ml.
CONCLUSION: this new LC-MS/MS assay is more sensitive than previous methods despite using a small plasma volume sample. It is particularly suitable for clinical studies on both parenteral and inhaled zanamivir.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21250845      PMCID: PMC3096760          DOI: 10.4155/bio.10.189

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  19 in total

1.  A new approach to evaluate regression models during validation of bioanalytical assays.

Authors:  T Singtoroj; J Tarning; A Annerberg; M Ashton; Y Bergqvist; N J White; N Lindegardh; N P J Day
Journal:  J Pharm Biomed Anal       Date:  2005-12-05       Impact factor: 3.935

2.  Avian influenza. WHO proposes plan to stop pandemic in its tracks.

Authors:  Dennis Normile
Journal:  Science       Date:  2006-01-20       Impact factor: 47.728

Review 3.  Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses.

Authors:  Frederick Hayden; Alexander Klimov; Masato Tashiro; Alan Hay; Amold Monto; Jennifer McKimm-Breschkin; Catherine Macken; Alan Hampson; Robert G Webster; Michèle Amyard; Maria Zambon
Journal:  Antivir Ther       Date:  2005

4.  Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays.

Authors:  C T Viswanathan; Surendra Bansal; Brian Booth; Anthony J DeStefano; Mark J Rose; Jeffrey Sailstad; Vinod P Shah; Jerome P Skelly; Patrick G Swann; Russell Weiner
Journal:  Pharm Res       Date:  2007-04-26       Impact factor: 4.200

5.  The next influenza pandemic: can it be predicted?

Authors:  Jeffery K Taubenberger; David M Morens; Anthony S Fauci
Journal:  JAMA       Date:  2007-05-09       Impact factor: 56.272

Review 6.  Drugs in development for influenza.

Authors:  David A Boltz; Jerry R Aldridge; Robert G Webster; Elena A Govorkova
Journal:  Drugs       Date:  2010-07-30       Impact factor: 9.546

7.  Determination of zanamivir in rat and monkey plasma by positive ion hydrophilic interaction chromatography (HILIC)/tandem mass spectrometry.

Authors:  Todd M Baughman; Wayne L Wright; Kathryn A Hutton
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-02-15       Impact factor: 3.205

8.  Liquid chromatographic-tandem mass spectrometric method for the determination of the neuraminidase inhibitor zanamivir (GG167) in human serum.

Authors:  G D Allen; S T Brookes; A Barrow; J A Dunn; C M Grosse
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1999-09-24

9.  Cell handling, membrane-binding properties, and membrane-penetration modeling approaches of pivampicillin and phthalimidomethylampicillin, two basic esters of ampicillin, in comparison with chloroquine and azithromycin.

Authors:  Hugues Chanteux; Isabelle Paternotte; Marie-Paule Mingeot-Leclercq; Robert Brasseur; E Sonveaux; Paul M Tulkens
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

10.  Determination of the novel sialic acid analog GG167 (GR121167X) in human urine by liquid chromatography: direct injection with column switching.

Authors:  D M Morris; B K Hussey; S L Geurin; K A Selinger
Journal:  J Pharm Biomed Anal       Date:  1995-12       Impact factor: 3.935

View more
  2 in total

1.  An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults.

Authors:  Sasithon Pukrittayakamee; Podjanee Jittamala; Kasia Stepniewska; Niklas Lindegardh; Sunee Chueasuwanchai; Wattana Leowattana; Aphiradee Phakdeeraj; Sutatip Permpunpanich; Warunee Hanpithakpong; Wirichada Pan-Ngum; Caroline Fukuda; Salwaluk Panapipat; Pratap Singhasivanon; Nicholas J White; Nicholas P J Day
Journal:  Antimicrob Agents Chemother       Date:  2011-06-20       Impact factor: 5.191

2.  Aqueous normal phase liquid chromatography coupled with tandem time-of-flight quadrupole mass spectrometry for determination of zanamivir in human serum.

Authors:  Jing Ge; Fengmao Liu; Eric H Holmes; Gary K Ostrander; Qing X Li
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2012-08-21       Impact factor: 3.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.